Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?

References

• Brannagan TH 3rd. Immune-mediated chronic demyelinating polyneuropathies. In: Neuroimmunology in Clinical Practice. Kalman B, Brannagan TH III (Eds). Blackwell, Oxford, UK, 123–138 (2008).
   Google Scholar
• Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann. Neurol.10(3), 222–226 (1981).
   PubMedGoogle Scholar
• Barohn RJ. Approach to peripheral neuropathy and neuronopathy. Semin. Neurol.18(1), 7–18 (1998).
   PubMed Web of Science ®Google Scholar
• Lunn MPT, Manji H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry66(5), 677–680 (1999).
   PubMed Web of Science ®Google Scholar
• Brannagan TH. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve39(5), 563–578 (2009).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology48(2), 321–328 (1997).
   PubMed Web of Science ®Google Scholar
• McCrone P, Chisholm D, Knapp M et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol.10(6), 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum.43(8), 1801–1808 (2000).
   PubMed Web of Science ®Google Scholar
• Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am. J. Kidney Dis.33(5), 829–839 (1999).
   PubMed Web of Science ®Google Scholar
• Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J. Neurol. Neurosurg. Psychiatry77(6), 800–802 (2006).
   PubMed Web of Science ®Google Scholar
• Oyama Y, Sufit R, Loh Y et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology69(18), 1802–1803 (2007).
   PubMed Web of Science ®Google Scholar
• Mahdi-Rogers M, Kazmi M, Ferner R et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J. Peripher. Nerv. Syst.14(2), 118–124 (2009).
   PubMed Web of Science ®Google Scholar
• Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J. Neurol. Neurosurg. Psychiatry79(5), 612–614 (2008).
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry72(1), 127–128 (2002).
   PubMed Web of Science ®Google Scholar
• Vermeulen M, Van Oers MHJ. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J. Neurol. Neurosurg. Psychiatry78(10), 1154 (2007).
   PubMed Web of Science ®Google Scholar
• Remenyi P, Masszi T, Borbenyi Z, Soos J, Siklos L, Engelhardt JI. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur. J. Neurol.14(8), E1–E2 (2007).
   PubMed Web of Science ®Google Scholar
• Brannagan TH, Pradhan A, Heiman-Patterson T et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology58(12), 1856–1858 (2002).
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Golightly MG, Brannagan TH III. High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. J. Neuroimmunol.190(1–2), 121–126 (2007).
   PubMed Web of Science ®Google Scholar
• Hu YP, Turner MJ, Shields J et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology128(2), 260–270 (2009).
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest.119(7), 2052–2061 (2009).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol.253(1), 98–108 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst.11(1), 30–46 (2006).
   PubMed Web of Science ®Google Scholar
• Marsh EA, Hirst CL, Llewelyn JG et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J. Neurol. (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis.67(9), 1322–1327 (2008).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DAS, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359(17), 1786–1801 (2008).
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin. Infect. Dis.43(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Nath DS, Kandaswamy R, Gruessner R, Sutherland DER, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc.37(2), 934–936 (2005).
   PubMed Web of Science ®Google Scholar
• Hattori N, Misu K, Koike H et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci.184(1), 57–63 (2001).
   PubMedGoogle Scholar